Home > Insider Trading > Filing (0000059478-16-000306)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
59478	Lilly Eli & Co	LLY	Pharmaceutical Preparations (2834)	350470950

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1359067	W Derica Rice	Lilly Corporate Center Indianapolis IN 46285	Evp-Global Services And Cfo	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2016-02-01	19,685	$0.00	56,560	No	4	M	Direct
Common Stock	Disposition	2016-02-01	9,146	$79.10	47,414	No	4	F	Direct
Common Stock	Disposition	2016-02-01	6,546	$78.36	40,868	No	4	S	Direct
Common Stock	Disposition	2016-02-03	3,937	$76.81	36,931	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	F	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Unit	Disposition	2016-02-01	19,685	$0.00	19,685	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2016-02-01	2016-02-01	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	7,190	Indirect	401(k)
Common Stock	329,140	Indirect	by wife
Common Stock	1,852	Indirect	401(k) - by wife

Footnotes

The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 2, 2015.
This transaction was executed in multiple trades at prices ranging from $78.12 to $78.63. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $76.46 to $76.94. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Reporting person disclaims beneficial ownership of these shares.
Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.